Introduction
This study is an attempt to measure the program effect of a chronic, complex Disease Management (DM) program from Accordant Health Services in a health plan setting versus a carefully defined control group. This is a randomized, control group analysis in which the DM program was offered to eligible members at AmeriHealth New Jersey (Intervention Group) but not to members in the control group at a large, affiliated plan in the metro Philadelphia, PA area (Control Group). The evaluation includes a baseline measure in the intervention and control populations with a re-measure of the outcomes following the intervention in the DM population. The analysis evaluates program impact across members matched on identification methodology, age, gender, disease, claims payment policy, other disease management initiatives and geographic location.
It is important to note that the significance of the matched time period comparison is that both populations would be exposed to the same new technologies and similar treatment patterns, reducing the need to make any adjustments for accommodating these biases, and in fact, no such adjustments were made. The only significant difference in intervention for the two groups was the presence of the AccordantCare® program in the Intervention Group.
Methodology
The authors used payer claims and membership data to identify members eligible for the program in a twelve-month Baseline year (10/01 to 9/02) and a subsequent twelve-month (10/02 to 9/03) Program year. Two payers were analyzed: one health plan with members primarily in New Jersey, where the disease management program was offered and one affiliated large plan with members primarily in the metro Philadelphia, PA area where the program was not offered. The claims payment policy for both plans are identical. Members included in the study were identified as having one of the following fourteen complex, chronic conditions: ALS, CIDP, Cystic Fibrosis, Gaucher, Hemophilia, Lupus, Multiple Sclerosis, Myasthenia Gravis, Myositis, Parkinson's, Rheumatoid Arthritis, Scleroderma, Seizures and Sickle Cell Anemia. Table 1 below.) The difference in the Baseline to Program mean PMPM was a +10% increase for the Control Group and a -8% decrease in the Intervention Group. The significant difference in PMPM seen in the Intervention Group versus the baseline in this carefully designed analysis can reasonably be attributed to the effects of the AccordantCare® program. Although many biases are designed out or otherwise controlled by the study design, some biases and limitations still possibly impact these results.
Results

Figure 1: Cost Comparison
Table 1: Gross Savings Analysis
Equivalence between Groups
To establish comparability, the equivalence of the two groups was measured using chi-square and t-tests. The majority of the evidence indicated statistically significant equivalence for gender and age across all conditions. (See Table 2 & 3 below.) Analyzing only the Non-Medicare populations for Seizures, the Control Group showed a +22.9% increase in mean costs from the Baseline to Program years while the Intervention Group showed a -25.5% decrease. Neither of these minor comparability issues is considered a significant bias. 
HMO and PPO Mix
As the Control Group has a higher percentage of PPO members than the Intervention Group and a lower percentage of HMO members (42% versus 29% for PPO and 24% versus 56% for HMO respectively across the Base and Program years) the authors wanted to investigate whether the differences in product line mix impacted the results, so, the gross savings for the PPO and HMO lines of business were analyzed. These results were consistent with the overall analysis showing a similar reduction in PMPM costs for HMO and PPO members (for example, 24.5% and 15.5% respectively in the Intervention Group). Therefore, the HMO/PPO Mix does not seem to account for the observed difference in PMPM between the Control and Intervention Groups.
Migration Analysis
Where did the noted PMPM decrease occur in the population? Did high cost members see a reduction in their PMPM, or were more low cost members maintained as low cost members over time? The authors measured the migration of members from a high-cost or Top Cohort to a lowcost or Bottom Cohort (Cost cohorts were divided at the median cost 
Conclusion
The difference in the observed cost trends in the Intervention and Control Groups was likely due to the AccordantCare Disease Management Program, and this effect was evident across multiple analyses and confirmed by statistical confidence testing. The study design is valuable as it measures program impact versus a very comparable control group (as supported by both the analytical design and by subsequent equivalence testing) over the same time period. It is the authors' conclusion that the disease management program is likely responsible for the observed difference between the Intervention and Control Group results.
A well-designed, targeted disease management program offered by a motivated, supportive health plan can play an important role in cost improvement strategies for members with uncommon, chronic diseases. It is the authors' hope and intent that similar study designs will be utilized within the disease management industry so as to provide a more accurate understanding of the value being driven by these programs.
